公开(公告)号：US20190055518A1

公开(公告)日：2019-02-21

申请号：US15570619

申请日：2016-04-29

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Joe Young-Ae

IPC: C12N5/0775 ,  C12N15/85

CPC classification number: C12N5/0665 ,  C12N5/0668 ,  C12N5/069 ,  C12N15/85 ,  C12N2501/60 ,  C12N2501/603 ,  C12N2501/605 ,  C12N2506/1346 ,  C12N2510/00 ,  C12N2740/15041 ,  C12N2740/16043

Abstract: The present invention relates to a method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors and, more specifically, a method for converting mesenchymal stem cells into endothelial cells by using Oct4, Nanog, Tal1, and LMO2, which are specific transcription factors. According to the present invention, the method for converting adult cells or mesenchymal stem cells, which are adult stem cells, into endothelial cells was developed by selecting two types of genes, which are less directly related to cancer induction, among cell reprogramming factors and two types of transcription factors, which are not expressed or expressed at a low level in mesenchymal stem cells, among transcription factors related to vascular development, and combining all four transcription factors. The method can be applied in the production of endothelial cells for forming regenerative tissue in tissue engineering and ischemic disease therapy.

公开(公告)号：US20180326003A1

公开(公告)日：2018-11-15

申请号：US15974647

申请日：2018-05-08

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Tai Gyu KIM ,  Hyun Il CHO

IPC: A61K38/17 ,  C07K14/725

CPC classification number: A61K38/1774 ,  C07K14/7051 ,  C12N2710/16211 ,  C12N2710/16222 ,  C12N2740/16043

Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.

公开(公告)号：US20180317891A1

公开(公告)日：2018-11-08

申请号：US15774002

申请日：2016-11-07

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： CHANG UK KIM

IPC: A61B10/00 ,  B01L3/00

CPC classification number: A61B10/007 ,  B01L3/50 ,  B65D25/04 ,  G01N33/493

Abstract: The present invention relates to a urine test container, Specifically, the present invention relates to a container capable of readily separating first urine while receiving whole urine in order to remove the inconvenience of discarding the first urine and putting the remaining urine in a container in a medical institution such as a hospital and a health care institution, because the quality of a test is decreased due to a plurality of epithelial cells included in the first urine in a urine test. A container for collecting the urine of a subject, which is one aspect of the present invention, comprises: a container for collecting urine; and a barrier film located within the container so as to divide the inside of the container, thereby separating a predetermined amount of the first urine, which is first collected from the urine, and the second urine differing from the first urine, wherein only the second urine is used in the urine test of the subject and the first urine and the second urine can be separated using the barrier film.

公开(公告)号：US20180256519A1

公开(公告)日：2018-09-13

申请号：US15903675

申请日：2018-02-23

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Mi La Cho ,  Chul Woo Yang ,  Sung Hwan Park ,  Seon Yeong Lee ,  Min Jung Park ,  Joo Yeon Jhun ,  Sun Woo Lim ,  Byung Ha Chung ,  Eun Kyung Kim ,  Jae Kyung Kim ,  Hyun-Sik Na ,  Se-Young Kim ,  Eun Jung Lee ,  Hyeon-Beom Seo

IPC: A61K31/155 ,  A61P37/06

CPC classification number: A61K31/155 ,  A61K31/436 ,  A61K2300/00 ,  A61P37/06

Abstract: The present invention relates to a composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin and, more specifically, to a composition for treating mitochondrial diseases caused by immunosuppressants, containing metformin; a pharmaceutical composition for preventing or treating immune diseases, containing, as active ingredients, metformin and an immunosuppressant, which is a target of rapamycin inhibitor (mTOR inhibitor); and a pharmaceutical composite formulation for preventing or treating immune diseases, containing, as ingredients, metformin and a mammalian target of rapamycin inhibitor, wherein the metformin and mammalian target of rapamycin inhibitor are administered simultaneously or separately, or administered in a predetermined sequence. The composition effectively alleviates mitochondrial dysfunction, occurring as a side effect of conventional immunosuppressants, while having a more improved immunosuppressive therapeutic effect, thereby being usable in prevention and treatment of transplant rejection, autoimmune diseases, inflammatory diseases, and the like, all of which require immunosuppression.

公开(公告)号：US10071055B2

公开(公告)日：2018-09-11

申请号：US14899558

申请日：2014-06-20

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTER

Inventor： Han Chang Kang ,  You Han Bae ,  Ha Na Cho

IPC: C12N15/11 ,  C07H21/02 ,  C07H21/04 ,  A61K9/16 ,  C07H21/00 ,  A61K48/00 ,  A61K47/59

CPC classification number: A61K9/1641 ,  A61K47/593 ,  A61K48/0041 ,  C07H21/00

Abstract: The present invention relates to a reducing or non-reducing polynucleotide polymer using a nucleotide from AMP, ADP, ATP, GMP, GDP, GTP, CMP, CDP and CTP, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), and N-hydroxy-succinimide (NHS) for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer. The present invention relates to a drug delivery carrier for delivering proteins or peptides to a targeted area through electrostatic attraction, by obtaining a negatively (−) charged polymer by using nucleotides to synthesize the reducing or non-reducing polymer, which is easily breakable due to disulfide bonds, and then bonding the negatively (−) charged polymer with a positively (+) charged protein or peptide, wherein a polymer derived from a non-viral drug delivery carrier containing the novel reducing or non-reducing polymer is capable of effectively enabling escape of a drug, delivered by means of proton buffering activity, from an endosome to other organelles in a cell.

公开(公告)号：US20180216065A1

公开(公告)日：2018-08-02

申请号：US15746773

申请日：2016-07-20

Applicant: The Catholic University of Korea Industry-Academic Cooperation Foundation

Inventor： Tai Gyu KIM ,  Mi Young PARK

IPC: C12N5/078 ,  C12N5/0775

CPC classification number: C12N5/0634 ,  A61K35/15 ,  A61P37/06 ,  C12N5/0665 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2506/115

Abstract: The present invention relates to a method for inducing differentiation myeloid-derived suppressor cells from cord blood CD34 positive cells and proliferating the same, and a use of the myeloid-derived suppressor cells. More specifically, myeloid-derived suppressor cells are induced to differentiate and proliferated by culturing cord blood CD34 positive cells in the presence of a cytokine cocktail of GM-CSF and SCF, such that myeloid-derived suppressor cells can be mass-produced in vitro, and the myeloid-derived suppressor cells can be used in preventing or treating immunorejection-related diseases such as graft-versus-host disease.

公开(公告)号：US10016376B2

公开(公告)日：2018-07-10

申请号：US15537486

申请日：2015-12-18

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Mi La Cho ,  Chul Woo Yang ,  Jong Young Choi ,  Sung Hwan Park ,  Min Jung Park ,  Seon Yeong Lee ,  Joo Yeon Jhun ,  Eun Jung Lee ,  Jae Kyung Kim ,  Eun Kyung Kim ,  Sun Woo Lim

IPC: A61K31/155 ,  A61K38/13 ,  A61K31/436

CPC classification number: A61K31/155 ,  A61K31/395 ,  A61K31/436 ,  A61K38/13

Abstract: Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects.

公开(公告)号：US09993526B2

公开(公告)日：2018-06-12

申请号：US14928762

申请日：2015-10-30

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Tai Gyu Kim ,  Hyun Il Cho

IPC: A61K38/17 ,  C07K14/705 ,  C07K14/725

CPC classification number: A61K38/1774 ,  C07K14/7051 ,  C12N2710/16211 ,  C12N2710/16222 ,  C12N2740/16043

Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.

公开(公告)号：US20170363532A1

公开(公告)日：2017-12-21

申请号：US15541287

申请日：2015-10-28

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Kyung Ja HAN ,  Won LEE

IPC: G01N15/14

CPC classification number: G01N15/1429 ,  C12M1/34 ,  G01N15/0227 ,  G01N15/1434 ,  G01N15/1459 ,  G01N21/4795 ,  G01N2015/1006 ,  G01N2015/1477

Abstract: Provided is a light scattering cell classification technology which can classify cells into various types and at the same time classify cells with very high accuracy despite the rotation of the cells. A cell analysis apparatus using a plurality of lasers, according to an embodiment of the present invention, comprises: a plurality of laser generators which are installed around a movement path through which cells to be classified are moved, and which irradiate laser beams at one measurement point on the movement path at different angles; a plurality of photodetectors, installed around the one measurement point, which collect a second laser beam, which is a laser beam generated as the laser beams irradiated from the laser generators are incident on the cells and then scattered; and a cell analysis unit which classifies the cells to be classified according to the second laser beam collected by the photodetectors.

公开(公告)号：US20170311118A1

公开(公告)日：2017-10-26

申请号：US15171073

申请日：2016-06-02

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY - ACADEMIC COOPERATION FOUNDATION

Inventor： TAE-SUK SUH ,  MIN-YOUNG LEE

IPC: H04W4/00 ,  G05B19/4099 ,  B33Y30/00 ,  B29L31/00 ,  B33Y50/02 ,  B33Y10/00

CPC classification number: G05B19/4099 ,  B29L2031/753 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y50/02 ,  B33Y80/00 ,  G05B2219/35134 ,  G05B2219/49007 ,  G06F2217/12 ,  G16H20/40 ,  G16H40/63 ,  H04W4/80

Abstract: The present invention relates to a method and system for manufacturing a compensator for total body irradiation using a camera, and more particularly, to a method and system for manufacturing a patient-tailored compensator of accurate values using a 3D printer based on information acquired through a camera including a space depth sensor and a motion tracking sensor to perform a precise treatment by minimizing the error that can be generated during the treatment. According to one aspect of the present invention, an apparatus for manufacturing a compensator applied to a treatment using total body irradiation (TBI) may include: a first sensor for sensing a space depth of a body of a patient; a second sensor for tracking and sensing a motion of the patient; a depth camera for generating three-dimensional scan information on the body of the patient using the information sensed by the first sensor and the second sensor; and a 3D printer for manufacturing the compensator using the three-dimensional scan information.